DXCM DEXCOM INC.

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care

(NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology.

During the conference, first-ever accuracy and performance data for Dexcom G7 15 Day,1 will be presented, showcasing an overall mean absolute relative difference (MARD) of 8.0%, making it the most accurate CGM.2 Dexcom also introduced new connectivity offerings and will present additional data throughout the conference demonstrating the benefits of Dexcom CGM for people with all types of diabetes. The announcements were made at the 18th International Conference on Advanced Technologies and Treatments for Diabetes, taking place March 19-22 in Amsterdam.

Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East

With a foreword from the International Diabetes Federation Europe, and recommendations for improving access to education and diabetes technology throughout, the Dexcom State of Type 2 report serves as a call to action for policymakers. It highlights the benefits of CGM technology for the 134 million4,5 people living with diabetes across Europe, the Middle East and North Africa—90-95%6,7 of whom have Type 2 diabetes.

  • Tech, not medication, is the future of T2 care: 52% of HCPs ranked access to CGM and education as having the potential to positively help people with Type 2 manage their condition in the next 10 years, compared with 38% who cited better or more effective medications.8
  • Reality exceeds expectation with CGM use: 77% of people with Type 2 diabetes who had not used CGM expected it to improve the lives of those with Type 2 compared to 93% of people with Type 2 diabetes who had used CGM and agreed it had a positive impact.8
  • HCPs see CGM as the ‘standard of care’: Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not. 96% of HCPs agreed those using multiple daily injections of insulin should receive CGM and 86% agreed those relying on basal insulin should be offered CGM.8
  • Barriers to CGM adoption and the case for improved access: HCPs see funding constraints (35%) and narrow inclusion criteria (20%) as the primary barriers to CGM adoption. 22% of HCPs believe increasing education for people with Type 2 diabetes could drive higher CGM usage.8

“With policymakers increasingly focused on digital transformation in healthcare, now is the time to push for greater investment in CGM technology as a core component of Type 2 management,” said Adrian Gut, senior director of international access, advocacy and value at Dexcom. “Enhancing CGM accessibility is crucial to tackling the Type 2 crisis. By ensuring equitable access to this life-changing technology, we can empower people with Type 2 to take control of their diabetes management, improve their quality of life and reduce complications. This will significantly improve public health outcomes and reduce long-term healthcare costs. Now is the time to make a transformative impact on the lives of millions.”

Read the full Dexcom State of Type 2 report at

Data demonstrates Dexcom G7 15 Day1 is the only CGM system with a MARD accuracy as low as 8.0%2

In a variety of symposia and presentations at ATTD this year, clinical evidence will continue to demonstrate the impact and value of Dexcom CGM among people with all types of diabetes. Of note, data evaluating the accuracy of its new Dexcom G7 15 Day sensor1 will be presented on March 20 at 1 p.m. CET in Hall D. With a MARD of 8.0%,2 Dexcom G7 15 Day will improve upon the accuracy of Dexcom G7 and will be the most accurate CGM. Dexcom G7 15 Day meets the FDA’s iCGM criteria and is currently under FDA review.

Dexcom CGM builds on “most connected CGM brand” with new integrations announced at ATTD

Dexcom is strengthening its position as the most connected CGM brand in the world3 by integrating Dexcom G7 with the Omnipod® 5 Automated Insulin Delivery System. Following availability in the US in 2024, Dexcom G7 is now available with Omnipod® 5 in Australia and The Netherlands and will be launching soon in Belgium, Canada and Switzerland. Dexcom is the only CGM brand that supports data sharing via the Follow app†,* when connected to Omnipod® 5 meaning users can gain more confidence in their diabetes management by sharing their glucose data with up to 10 friends, family members or caregivers.

Dexcom G7 now also directly connects with NovoPen® 6 and NovoPen Echo® Plus in Germany and will soon be available in more markets. By seamlessly integrating Dexcom CGM data with NovoPen® 6 and NovoPen Echo® Plus insulin data in one app, healthcare professionals gain a comprehensive, actionable view of a patient’s glucose and insulin patterns. With features uniquely designed to help prevent insulin stacking and dosing errors when used with a smart pen, Dexcom G7 offers HCPs the tools to manage these critical risks with greater confidence. This new and innovative connection comes as the Dexcom State of Type 2 report reveals 100% of HCPs in Germany think CGM should be the standard of care for those treating their Type 2 diabetes with MDI.8

For more information about Dexcom presentations at ATTD and to register to virtually attend the conference, visit . To read the Dexcom State of Type 2 Report, visit .

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit .

Category: IR

To learn more about insulin pump integration and compatibility with Dexcom CGM systems, visit Dexcom.com/integrate. Smart devices sold separately. For a list of compatible devices, visit Dexcom.com/compatibility.

1 Dexcom G7 15 Day is 510(k) pending. Not available for sale or distribution in the United States. 2 Garg S et al. Performance and Accuracy of 15-Day G7 Continuous Glucose Monitor. 2024. Abstract 1240 ATTD 2025. 3 Dexcom, Data on File, 2024 4 Diabetes Atlas, IDF Atlas Factsheet 2021 Europe, Accessed March 2025 ; 5 Diabetes Atlas, IDF Atlas Factsheet 2021 MENA, Accessed March 2025 6 Statista, Diabetes in Europe - Statistics & Facts, Accessed March 2025 7 Oncohema Key, Type 2 Diabetes in the Middle East and North Africa (MENA), Accessed March 2025 8 Dexcom State of Type 2 Report, Dexcom Data on File, 2025

Users should always confirm readings and trend on the Dexcom G7 app or receiver before making treatment decisions.

* Separate Dexcom Follow app and internet connection required.

EN
19/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DEXCOM INC.

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Dexcom Inc: 2 directors

Two Directors at Dexcom Inc sold 16,184 shares at between 84.285USD and 85.110USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

OSK OSHKOSH CORP
DXCM DEXCOM INC.
XRAY DENTSPLY SIRONA INC.
WING WINGSTOP INC.
VRTS VIRTUS INVESTMENT PARTNERS INC.
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
STKS ONE GROUP HOSPITALITY
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
SFST SOUTHERN FIRST BANCSHARES
RGNX REGENXBIO INC.
RCKY ROCKY BRANDS
PRGO PERRIGO CO. PLC
MPWR MONOLITHIC POWER SYSTEMS INC.
JRVR JAMES RIVER GROUP HOLDINGS LTD
IRM IRON MOUNTAIN INC.
GPC GENUINE PARTS COMPANY
GD GENERAL DYNAMICS CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CROX CROCS INC.
CAL CALERES INC.
BKE BUCKLE INC.
ASC ARDMORE SHIPPING
AMOT ALLIED MOTION TECHNOLOGIES
ACAD ACADIA PHARMACEUTICALS INC.
SBL SAFE BULKERS INC.
LPG DORIAN LPG
MEG. MEG ENERGY CORP.
MDU MDU RESOURCES GROUP INC
NAT NORDIC AMERICAN TANKERS LIMITED
EVTC EVERTEC INC.
FSLR FIRST SOLAR INC.
IONS IONIS PHARMACEUTICALS INC.
NMIH NMI HOLDINGS INC. CLASS A
AGYS AGILYSYS INC.
SJM J.M. SMUCKER COMPANY
FIZZ NATIONAL BEVERAGE CORP.
NHC NATIONAL HEALTHCARE CORP.
INSW INTERNATIONAL SEAWAYS INC.
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
CELH CELSIUS HOLDINGS INC.
AMD ADVANCED MICRO DEVICES INC.
TTEC TTEC HOLDINGS INC.
AVGO BROADCOM INC.
ST SENSATA TECHNOLOGIES HOLDING PLC
ELAN ELANCO ANIMAL HEALTH INC.
MEC MAYVILLE ENGINEERING
DELL DELL TECHNOLOGIES INC CLASS C
CSTM CONSTELLIUM SE CLASS A
OI O-I GLASS INC
BWMN BOWMAN CONSULTING GROUP LTD
DINO HOLLYFRONTIER CORP
EVEX EVE HOLDING INC
SPXC SPX TECHNOLOGIES INC
WEST WESTROCK COFFEE COMPANY LLC
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
AGEN AGENUS INC.
ARDT ARDENT HEALTH PARTNERS INC
PCT PROVIDENT CAP TR II SKIS 8.75%29
MKTW MARKETWISE INC
 PRESS RELEASE

Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medi...

EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insights into access to care and perceptions of diabetes technology. During the conference, first-ever accuracy a...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch